CEO of Medigen:"Medigen designed a trial to discern whether we...

CEO of Medigen:

"Medigen designed a trial to discern whether we can reduce recurrence rates for these patients. Our 172-patient Phase II study demonstrated fantastic results in suppressing the recurrence of the so-called ‘residual’, or satellite, tumors—and I believe our Phase III study will fare even better. "

That interview was mentioned several times before... but worth a read once again :-)!! IMO

http://www.pharmaboardroom.com/article/interview-stanley-chang-chairman-and-ceo-medigen-biotechnology-corp